NASDAQ:AMRS
Delisted
Amyris Stock News
$0.0500
+0 (+0%)
At Close: Nov 27, 2023
Amyris (AMRS) Q4 2021 Earnings Call Transcript
11:30pm, Tuesday, 01'st Mar 2022 The Motley Fool
AMRS earnings call for the period ending December 31, 2021.
Amyris (AMRS) Q4 2021 Earnings Call Transcript
11:30pm, Tuesday, 01'st Mar 2022 The Motley Fool
AMRS earnings call for the period ending December 31, 2021.
Amyris, Inc. (AMRS) CEO John Melo on Q4 2021 Results - Earnings Call Transcript
04:36pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Amyris sees consumer revenue growing 150% this year
03:48pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Amyris (AMRS) is expecting a very bullish 2022, so much so that its newly issued financial guidance calls for a 150% increase in consumer revenue year over year.
Amyris, Inc. 2021 Q4 - Results - Earnings Call Presentation
03:03pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Amyris GAAP EPS of -$0.43 misses by $0.23, revenue of $64.78M beats by $10.15M (NASDAQ:AMRS)
01:07pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Amyris press release (NASDAQ:AMRS): Q4 GAAP EPS of -$0.43 misses by $0.23.Revenue of $64.78M (-18.7% Y/Y) beats by $10.15M.
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
12:51pm, Tuesday, 01'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Editas Gains On Resolution Of CRISPR Gene Editing Patent Case
Editas Medicine, Inc. (NASDAQ: EDIT) sai
Amyris, Inc. (AMRS) CEO John Melo on Q4 2021 Results - Earnings Call Transcript
11:36am, Tuesday, 01'st Mar 2022
Amyris, Inc. (AMRS) CEO John Melo on Q4 2021 Results - Earnings Call Transcript
Amyris Q4 2021 Earnings Preview
04:45pm, Monday, 28'th Feb 2022 Seeking Alpha
Amyris (NASDAQ:AMRS) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open.Consensus EPS estimate is -$0.16 (-433.3% Y/Y)
Amyris (AMRS) to Report Q4 Earnings: What's in the Cards?
12:07pm, Monday, 28'th Feb 2022 Zacks Investment Research
Amyris (AMRS) is likely to have benefited from continued strong growth in its consumer brands amid supply-chain headwinds in Q4.
Amyris, Inc. (AMRS) Gains As Market Dips: What You Should Know
11:15pm, Monday, 14'th Feb 2022 Zacks Investment Research
Amyris, Inc. (AMRS) closed the most recent trading day at $4.32, moving +1.89% from the previous trading session.
Amyris, Inc. (AMRS) Gains But Lags Market: What You Should Know
11:15pm, Tuesday, 08'th Feb 2022 Zacks Investment Research
Amyris, Inc. (AMRS) closed at $3.96 in the latest trading session, marking a +0.25% move from the prior day.
Amyris, Inc. (AMRS) Gains But Lags Market: What You Should Know
07:59pm, Tuesday, 08'th Feb 2022
Amyris, Inc. (AMRS) closed at $3.96 in the latest trading session, marking a +0.25% move from the prior day.
Amyris: Surviving The Perfect Storm
06:43pm, Thursday, 03'rd Feb 2022
The Synthetic Biology sector underperformed the overall market in Q4 2021. Temporary supply chain disruptions drove the bulk of revenue headwinds.
